ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Updated Software Solutions Offer Increased Productivity and Data Confidence

Thermo Scientific software enhancements enable improved usability, efficiency and performance across a wide range of workflows

ASMS 2022 - Thermo Fisher Scientific Inc., the world leader in serving science, has released new software to scientists in biopharmaceutical, proteomics, and small molecule settings to enable more comprehensive analysis of their data. The latest software updates bring new features that enable researchers to extract more information from their new and existing data, streamline data interpretation, and standardize reporting with increased ease of use.

“It’s essential that we continue to develop our software platforms to meet the increasing data analysis needs of our customers, expanding analytical capabilities and providing greater biological insights,” said August Specht, vice president, global research and development, chromatography and mass spectrometry, Thermo Fisher Scientific. “Thanks to the latest upgrades to our software suites, we can give scientists access to the newest technologies and built-for-purpose platforms to quickly and confidently turn data into meaningful results.”

Thermo Fisher Scientific is showcasing these latest software releases during the 70th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, being held June 5-9, 2022 in Booth 400 at the Minneapolis Convention Center, Minneapolis, Minnesota and at the Hilton Minneapolis Grand Ballrooms E, F, G.

A complete solution for confident and streamlined biotherapeutic characterization

The newest Thermo Scientific BioPharma Finder 5.1 software offers a complete solution for oligonucleotide analysis and biotherapeutic characterization workflows, providing increased confidence in results by comprehensively characterizing mass spectrometry data using advanced algorithms. Oligonucleotide-based biotherapeutics present unique challenges for characterization due to their complexity. The new software provides an enhanced suite of built-for-purpose tools to overcome these challenges and meet the needs of this rapidly growing field, quickly and confidently turning complex data into meaningful results. Improvements to the kinetic prediction model for oligonucleotides enable more confident prediction and matching. Improved data review tools and tables offer streamlined review and results reporting of complex oligonucleotide data sets.

Redefining proteomics research capabilities by leveraging artificial intelligence

Proteomics scientists can now benefit from the newest Thermo Scientific Proteome Discoverer 3.0 software in combination with the CHIMERYS intelligent search algorithm by MSAID, leveraging artificial intelligence to more fully interpret data generated by Thermo Scientific Orbitrap mass spectrometers. This innovative approach substantially increases the number of unique peptide identifications, improves protein coverage and quantitation capabilities, and enables scientists to discover more in their data. The new intelligent search algorithm also facilitates higher throughput analysis and wide-isolation window data-dependent acquisition for synergistic performance enhancements. This deeper mining of data expands the ways in which proteomics scientists can acquire and apply their data.

Improving untargeted small molecule workflows with new peak detection and quality algorithms

Small molecule researchers can now leverage a faster and more sensitive peak detection algorithm with the newest Thermo Scientific Compound Discoverer 3.3 software to detect more compounds in less time. Filtering large data sets down to relevant compounds is now easier than ever by using the new peak quality functionality to streamline data processing and review. Improve confidence in compound annotations through MSn spectral tree search capabilities in tandem with the Thermo Scientific mzCloud spectral library to address the most challenging unknown compounds. Compound Discoverer 3.3 software, which has been optimized for processing large datasets and detecting low-abundance compounds, will support scientists in metabolomics, pharmaceutical, environmental, food safety, clinical, and forensics applications to acquire the results they need to drive science forward.

For more information on the Thermo Fisher Scientific solutions exhibited at ASMS 2022, please visit www.thermofisher.com/ASMS.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  210.00
+2.08 (1.00%)
AAPL  264.18
-8.77 (-3.21%)
AMD  200.21
-3.47 (-1.70%)
BAC  49.83
-2.47 (-4.72%)
GOOG  311.43
+4.28 (1.39%)
META  648.18
-8.83 (-1.34%)
MSFT  392.74
-8.98 (-2.24%)
NVDA  177.10
-7.79 (-4.21%)
ORCL  145.40
-4.91 (-3.27%)
TSLA  402.51
-6.07 (-1.49%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.